Cyclacel Pharmaceuticals Reports First Quarter 2014 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/6/2026
- Nasdaq notches record high close as investors focus on earnings
- Oil slips on rising Mideast crude exports, G7 stocks release
- Intel stock slides as TSMC explores Terafab tie-up, analyst flags share losses
- Schneider Electric to acquire PTC for $22.6 billion in all-cash deal
- Five things to watch in markets in the week ahead
- Citi cuts investment banking analyst program to two years - Bloomberg
- Paramount Skydance to close WBD deal, change ticker to SKYD
- Nasdaq notches record high close as investors focus on earnings
- This multi-trillion stock is "cheap and getting cheaper": Morgan Stanley
- Schneider Electric to acquire PTC for $22.6 billion in all-cash deal
Cyclacel Pharmaceuticals, Inc. (CYCC) Posts Q1 Loss of 25c/Share
May 13, 2014 4:44 PM EDTCyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) reported Q1 EPS of ($0.25), $0.01 better than the analyst estimate of ($0.26).
"We are pleased to report that we have enrolled our first European patients in our Phase 3 SEAMLESS trial in AML and expect to open approximately 80 European sites,... More



